368 results on '"Lin, Chien-Chin"'
Search Results
2. Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia
3. Stellae-123 gene expression signature improved risk stratification in Taiwanese acute myeloid leukemia patients
4. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms
5. Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations
6. Early Therapeutic Drug Monitoring Optimizes Teicoplanin Use in Febrile Neutropenic Patients with Hematological Malignancies
7. Epidemiology, Treatment Outcomes, and Prognosis of Myelodysplastic Syndromes/Neoplasms in Taiwan: Real-World Insights and Trends
8. Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target
9. Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
10. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
11. Kinome expression profiling improves risk stratification and therapeutic targeting in myelodysplastic syndromes
12. Lineage switch of KMT2A-rearranged adult B-lineage acute lymphoblastic leukemia following bispecific T-cell engager and monoclonal antibody therapy
13. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification
14. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML
15. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
16. The clinical and biological characterization of acute myeloid leukemia patients with S100A4 overexpression
17. The effect of time spent sitting and excessive gaming on the weight status, and perceived weight stigma among Taiwanese young adults
18. Assessing exposure to weight stigma: development and initial validation of the Weight Stigma Exposure Inventory (WeSEI).
19. HOPX as a tumour‐suppressive protein in T‐cell acute lymphoblastic leukaemia.
20. Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy.
21. Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair
22. Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
23. A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes
24. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
25. Synergistic effect of concurrent high molecular risk mutations and lower JAK2mutant variant allele frequencies on prognosis in patients with myelofibrosis—insights from a multicenter study
26. IDH2 mutation accelerates TPO‐induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo.
27. Serial regression of primary gastric diffuse large B cell lymphoma after Helicobacter pylori eradication therapy: A case report.
28. A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients
29. Early Therapeutic Drug Monitoring Optimizes Teicoplanin Use in Patients with Hematological Malignancies
30. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification
31. Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125
32. Knock-out of Hopx disrupts stemness and quiescence of hematopoietic stem cells in mice
33. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax
34. Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan
35. Phf6-null hematopoietic stem cells have enhanced self-renewal capacity and oncogenic potentials
36. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients
37. Comparison of the 2022 World Health Organization Classification and International Consensus Classification in Myelodysplastic Syndromes/Neoplasms
38. Clinico-Genetic and Prognostic Analyses of 635 Patients with Myelodysplastic Neoplasms Based on the 2022 World Health Organization Classification
39. Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information
40. MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
41. Oral Abstract: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
42. POSTER: MDS-157 Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
43. P703: THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS
44. P720: A BONE MARROW MICROENVIRONMENTAL CELL SIGNATURE SCORING SYSTEM INDEPENDENTLY PREDICTED SURVIVAL AND DRUG RESISTANCE IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS
45. S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
46. S171: HIGHER MDMX EXPRESSION WAS ASSOCIATED WITH HYPOMETHYLATING AGENT RESISTANCE AND WORSE SURVIVAL IN MYELODYSPLASTIC SYNDROME PATIENTS, INFERRING IT A POTENTIAL THERAPEUTIC TARGET
47. P721: VALIDATION OF THE MOLECULAR INTERNATIONAL PROGNOSTIC SCORING SYSTEM IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES DEFINED BY INTERNATIONAL CONSENSUS CLASSIFICATION
48. A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes
49. ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
50. A case of acute myelomonocytic leukemia morphologically mimicking lymphoblastic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.